<DOC>
	<DOCNO>NCT02177032</DOCNO>
	<brief_summary>Demonstrate non-inferiority immune response new versus currently recommend intradermal regimen rabies vaccine administer without rabies immunoglobulins healthy subject ≥ 1 year age .</brief_summary>
	<brief_title>Safety Immunogenicity Two Intradermal Rabies Vaccine Regimens Administered With Without Human Rabies Immunoglobulin Subjects ≥ 1 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Healthy male female ≥ 1 year age 2 . Individuals/ individual 's parent legal guardian give write consent 3 . Individuals good health 4 . Individuals comply study procedure 1 . Behavioral cognitive impairment psychiatric disease . 2 . Unable comprehend follow require study procedure whole period study . 3 . History illness ongoing illness may pose additional risk individual he/she participate study . 4 . Individuals ≥ 1 ≤ 17 year age , ever malignancy . 5 . Individuals ≥ 18 year age , within last 5 year , malignancy ( exclude nonmelanotic skin cancer ) lymphoproliferative disorder . 6 . Known suspected impairment immune system ( include limit HIV , autoimmune disorder , immunosuppressive therapy applicable ) . 7 . Female childbearing potential use `` acceptable contraceptive method '' least 2 month prior study entry . 8 . Female childbearing potential , refusal use `` acceptable birth control method '' day 50 . 9 . Female childbearing potential , positive pregnancy test prior enrollment . 10 . Received blood , blood product and/or plasma derivative parenteral immunoglobulin preparation previous 12 week . 11 . Allergic vaccine component . 12 . Allergic human rabies immunoglobulin component . 13 . Contraindication precaution rabies vaccination . 14 . Contraindication precaution man rabies immunoglobulin administration . 15 . Planning receive antimalaria medication ( e.g . Mefloquine ) 14 day prior day 1 vaccination day 50 . 16 . Participating clinical trial another investigational product 30 day prior first study visit intent participate another clinical study time conduct study . 17 . Received vaccine within 14 day ( inactivated vaccine ) 28 day ( live vaccine ) prior enrollment study plan receive vaccine within 28 day study vaccine . 18 . Body temperature ≥ 38.0°C ( ≥ 100.4°F ) within 3 day intend study vaccination . 19 . Received rabies vaccine rabies immunoglobulin expose rabies . 20 . Part study personnel immediate family member study personnel conduct study . 21 . Current history drug alcohol abuse within past 2 year .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Rabies vaccine</keyword>
	<keyword>intradermal</keyword>
	<keyword>human rabies immunoglobulin</keyword>
</DOC>